AMNEAL PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2020-06-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2020-03-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | $0.00 derived: sum of 3 quarters · filed 2023-03-03 | $0.00 10-K · filed 2023-03-03 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $33.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $33.00K derived: sum of 3 quarters · filed 2022-03-01 | $389.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | $33.00K derived: sum of 2 quarters · filed 2022-03-01 | $389.93M derived: sum of 3 quarters · filed 2022-03-01 | $381.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $389.93M derived: sum of 2 quarters · filed 2022-03-01 | $381.60M derived: sum of 3 quarters · filed 2022-03-01 | $371.72M 10-K · filed 2022-03-01 |
| 2019-09-30 | $389.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $381.57M derived: sum of 2 quarters · filed 2020-11-06 | $371.68M 10-Q · filed 2020-11-06 | $371.36M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$18.21M 10-Q · filed 2020-08-06 | -$18.54M derived: sum of 3 quarters · filed 2021-03-01 | -$12.65M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$9.88M 10-Q · filed 2020-05-11 | -$10.21M derived: sum of 2 quarters · filed 2021-03-01 | -$4.33M derived: sum of 3 quarters · filed 2021-03-01 | -$18.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.55M derived: sum of 2 quarters · filed 2021-03-01 | -$8.93M derived: sum of 3 quarters · filed 2021-03-01 | -$9.44M 10-K · filed 2021-03-01 |
| 2018-09-30 | $5.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$8.60M derived: sum of 2 quarters · filed 2019-11-07 | -$9.11M 10-Q · filed 2019-11-07 | -$7.83M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$14.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$14.99M 10-Q · filed 2019-08-05 | -$13.72M derived: sum of 3 quarters · filed 2020-03-02 | -$14.49M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$512.00K 10-Q · filed 2019-05-09 | $764.00K derived: sum of 2 quarters · filed 2020-03-02 | -$14.00K derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $498.00K derived: sum of 2 quarters · filed 2020-03-02 | $742.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$778.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$534.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $244.00K 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $121.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |